Meiragtx Holdings Plc Stock Price, News & Analysis

MeiraGTx Holdings plc (Nasdaq: MGTX) announced the presentation of twelve-month results from its ongoing Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy for X-linked retinitis pigmentosa (XLRP), at the American Academy of Ophthalmology 2020 Virtual Meeting from November 13-15, 2020. The data, which will be shared by presenter Michel Michaelides, has shown significant improvements in vision and retinal sensitivity. AAV-RPGR has received FDA Fast Track and Orphan Drug designations, enhancing its development prospects.

MeiraGTx Holdings plc (MGTX) presented nine-month data from its Phase 1/2 clinical trial of AAV-RPGR, a gene therapy for X-linked retinitis pigmentosa, at the EURETINA 2020 Virtual Congress. The results showed significant improvements in retinal sensitivity and vision-guided mobility compared to untreated eyes. Specifically, six out of seven patients in low and intermediate dose cohorts maintained or improved retinal sensitivity. The therapy is well-tolerated, with plans to advance into a Phase 3 pivotal study following the ongoing success.

MeiraGTx (Nasdaq: MGTX), a clinical stage gene therapy company, announces that CEO Alexandria Forbes, Ph.D., will present at the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:30 p.m. ET. A live webcast of the event will be available on the company's Investors page, with a replay accessible for 30 days post-presentation.

MeiraGTx focuses on developing therapies for unmet medical needs in inherited retinal diseases, neurodegenerative diseases, and severe xerostomia, and boasts a robust pipeline of clinical and preclinical programs.

MeiraGTx Holdings plc (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:30 p.m. ET. A live webcast will be available on the company's investor webpage, with a replay accessible for 30 days after the event. MeiraGTx is a clinical-stage gene therapy company focusing on unresolved medical needs in inherited retinal diseases, neurodegenerative diseases, and xerostomia, with six clinical development programs and strong capabilities in viral vector design and gene therapy manufacturing.

MeiraGTx Holdings plc (Nasdaq: MGTX) announced significant progress in its Phase 1/2 clinical trial of AAV-RPGR, a gene therapy for X-linked retinitis pigmentosa (XLRP). The latest data, to be presented at the EURETINA 2020 Virtual Meeting on October 3, showcases nine-month results indicating positive outcomes in vision improvement and safety. AAV-RPGR, developed in collaboration with Janssen, targets RPGR gene mutations, which are responsible for over 70% of XLRP cases. The therapy has received several designations, including Fast Track and Orphan Drug by the FDA.

MeiraGTx Holdings plc (MGTX) announced its Q2 2020 results, highlighting positive initial data from the Phase 1/2 trial of AAV-RPGR for X-linked retinitis pigmentosa, leading to its advancement into the Phase 3 Lumeos trial. The company also unveiled plans for new manufacturing facilities in Shannon, Ireland, set to enhance production capabilities. Financially, MeiraGTx reported a net loss of $25.4 million and cash reserves of $194.8 million. License revenue increased to $2.5 million, while R&D expenses rose to $16.2 million, influenced by costs from clinical trials and a recent acquisition.

MeiraGTx Holdings (MGTX) announced positive results from the Phase 1/2 clinical trial of AAV-RPGR, aimed at treating X-linked retinitis pigmentosa (XLRP). Significant improvements in vision were observed in patients after six months, with favorable safety and efficacy profiles noted. As a result, MeiraGTx and Janssen plan to progress AAV-RPGR into the Phase 3 Lumeos trial. The findings were presented at the ASRS 2020 Virtual Annual Meeting, highlighting the potential of AAV-RPGR as a significant advancement in treating a disease currently lacking approved therapies.

MeiraGTx Holdings plc (MGTX) reported Q1 2020 financial results, highlighting a net loss of $15.7 million, or $0.43 per share, an improvement from $18 million, or $0.62 per share, in Q1 2019. The company had cash, cash equivalents, and restricted cash totaling approximately $211 million, sufficient to fund operations into 2022. License revenue rose to $4.2 million, driven by a collaboration agreement with Janssen. R&D expenses decreased to $8.1 million, while G&A expenses increased to $11.8 million. MeiraGTx remains focused on its clinical programs despite COVID-19 challenges.

MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage gene therapy company, will have its CEO, Alexandria Forbes, present at the Virtual Bank of America Securities 2020 Health Care Conference on May 12, 2020, at 10:20 a.m. ET. Interested parties can access the live webcast on the Company's Investors page, with a replay available for 30 days. MeiraGTx specializes in gene therapies targeting inherited retinal diseases, neurodegenerative diseases, and xerostomia, supported by a strong pipeline and advanced manufacturing capabilities.